العربية
Русский
Português
中文 (中国)
Türkçe
Spanish
Polski
Ελληνικά
Čeština
Norsk Nynorsk
How we combine AI and human gut microbiome
The gut microbiome is analyzed using artificial intelligence technologies. Upon receipt of the sample, our contracted laboratories conduct the NGS-based analysis. The ENBIOSIS software processes the raw DNA data, determines which bacterial groups live in the person’s gut at the taxonomic level, and, most importantly, defines the ecological and functional relationships between them. The details of the microbiome analysis are provided in the ENBIOSIS Microbiome Modulation Report.
ENBIOSIS AI technology
To train the machine learning models, we compiled a microbiome database using available open-source data from the American Gut Project, the Human Microbiome Project, the Flemish Gut Flora Project, and the in-house data we possess. The database consists of microbiome data and lifestyle & health information from over 46,000 individuals. With our expanding biobank, our AI tech is continuously improving itself.
Probiotic recommendation system
Probiotics are live microorganisms providing health benefits when consumed as supplementations. Each person’s microbiome is deficient of different probiotic organisms.Analyzing each individual’s microbiome at microbial gene resolution, ENBIOSIS provides personalized probiotics suggestions for promoting health, as well as adverse the complications of chronic diseases.
ENBIOSIS AI-based nutrition model
In order to evaluate food-microbiota relationship, we compiled a nutrient database containing categories: carbohydrates, proteins, lipids, vitamins/minerals, phytochemicals, food additives, specific food, fermented food. Micronutrients that are associated with the growth/inhibation of certain microorganisms in in-vivo studies are determined by a meta-analysis.
The final database includes micronutrients and their target microorganisms. When a preferred microbiome modulation (i.e. towards a healthier state, in favor of probiotic composition) is determined, the related micronutrients receive scores accordingly. A single micronutrient can have multiple targets, as well as an organism can be targeted by multiple micronutrients. This results in repetitive preferences of certain micronutrients, thus differential grading in a broad range.
The final scores are a relative grading scaled to 0-10 range. Similarly, the food scorings are the cumulative scoring of food items linearly weighted by their micronutrient ingredients.
ENBIOSIS next-gen probiotics and live biotherapeutics
Our AI-based biomarker discovery technology data-mine vast amounts of microbiome data to discover genetic entities associated with human health. Throughout our quest in our proprietary micro-biobank, we have discovered striking biomarkers (bacterial genes and biosynthetic gene clusters as large DNA segments) that can potentially deliver unprecedented health benefits.
We initiated a research and development program to produce genetically engineered microorganisms to integrate mentioned biomarkers delivering next-generation of probiotics.
Microbiome science: where health and discovery meet
ENBIOSIS biomarkers
are used for
Personalized nutrition and diet technologies
Microbiome based liquid-biopsy and diagnostic
Next generation probiotics and biotherapeutics
Wellness
- Microbiome analysis report
- Personalized diet model
- Personalized pre- & probiotic suggestions
Diagnostic
Our microbiome-based liquid-biopsy product family provides non-invasive early disease detection biotech kits and software.
AI agents discover liquid biopsy biomarkers via data-mining ENBIOSIS Biobank. Our bioscience team then translates these biomarkers into biotech products.
Therapeutic
Long term products
*Therapeutic: 78% Success In Treating IBS, IBS Management Service On Sale, %83 Success In Treating Chronic Constipation
- Disease management with microbiome diet
- Bacteriophage therapy
- Personal therapy solutions
- Biotherapeutics
- Smart microbiome transplant
ENBIOSIS microbiome platform
ENBIOSIS generic framework gathers microbiome samples and lifestyle&health information by mail-in-kits or on-site from the users via a panel of applications. The samples are subject to next-generation sequencing and the data generated are placed in the biobank to be mined by AI algorithms to return the specific solutions. This generalized pipeline applicable to a range of add-on solutions sharing the same operation system.
IP & Competitive landscape
Trade screet
In-house & Protected
Patent & Licences
Competitive landscape
- Data-driven novel biomarkers
- SOTA non-invasive diagnostics
- Microbiome based health network supported by ENBIOSIS Biobank
- Unified platform for a spectrum of applications
Projects
New generic probiotics
Diagnosis of gastrointestinal diseases based on gut microbiome
GMO probiotics
Stage
Phase 1
Phase 2 – 3
Phase 1
Vertical
Wellness
Diagnostic
Theurapatic
Duration
Long-term
Short-term
Long-term
Phase 1: Basic study, Data collection, Bioinformatic
Phase 2: Wet lab, Algo. development
Phase 3: Clinical study, Certificates
Phase 4: Sale
Clinical studies
* Our clinical study on IBS has demonstrated a success rate of 78% and the results were published in Gut Microbes (Impact Factor: 11.7).
* Our clinical study on chronic constipation has demonstrated a success rate of 83% and the results were published in JCM (Impact Factor: 5.1).
We intend to expand our business by introducing new products that will be the result of an extensive research.
Upcoming products
New generic probiotics & GMO probiotic
We have isolated novel probiotics strains from healthy human microbiome that could be employed as probiotics supplements. Additionally, our biomarker discovery algorithms have mined biosynthetic gene clusters that are strong candidates for promoting human health when integrated into GMO probiotics.
We need to collaborate with synthetic biology talents to engineer GMO probiotics and proceed to industrial-level supplement production.
Discover breakthroughs in our microbiome research
Clinically proven AI-based solution for gut health
Microbiome-based approach on IBS
Over the past decade extensive research has proved that the biological diversity of the gut microbiome and a disruption in the balance of the ecosystem (dysbiosis) play an important role in the pathogenesis of gut diseases.
At ENBIOSIS Biotechnology, we analyze the gut microbiome using artificial intelligence technologies and recommend foods and supplements that can modulate the microbiome and drive it towards a targeted healthier state. We aim to improve the gut microbiome profile by selectively feeding the gut bacteria with the right nutrients and supplements tailored to the individual’s microbiome needs.
IBS clinical study
Irritable bowel syndrome (IBS), also known as spastic colon, is a functional rather than a structural disorder with a multifactorial pathogenesis. IBS significantly lowers the quality of life of the affected individuals.
IBS is one of the most common chronic functional bowel disorders in adults. 11% of the world’s population is estimated to suffer from IBS. This rate varies between 1.1% and 45.0% on a country-by-country basis. Our clinical study demonstrated a success rate of 78% on IBS. It is the first and only successful IBS management option that utilized microbiome-specific personalized nutrition recommendations.
Chronic constipation clinical study
Chronic constipation is a condition in which a person has infrequent bowel movements or passes hard stools. It can cause discomfort, bloating, and abdominal pain. While many people suffering from chronic constipation experience it for some time, the majority suffers from this problem for a long time and looks for different alternatives. This gut problem is very common with a global prevalence of 15%, which can increase by around 30% in the elderly population. Our clinical study demonstrated a success rate of 83% on chronic constipation. Microbiome modulation through personalized nutrition is an alternative way to deal with constipation.
Multicenter IBS clinical study
Our latest multicenter IBS study demonstrated the superiority of the Enbiosis AI-powered personalized microbiome diet over the FODMAP diet, long considered the gold standard for managing IBS. Following the 6-week intervention, we observed significant improvements, including positive shifts in both alpha and beta diversity, IBS symptoms across all subtypes, quality of life, depression, and anxiety levels, as well as beneficial bacteria levels among patients who followed the personalized microbiome diet. The results of this study have already been presented at prestigious events worldwide and published in the American Journal of Gastroenterology, the #1 clinical journal in gastroenterology and hepatology, providing practical and professional support for GI clinicians.
Presented at
